Curative Surgery After 3-Drug Chemotherapy Regimen Extends Survival in Patients with Locally Advanced CCA

Web Exclusives — March 22, 2022

The current standard first-line therapy for advanced cholangiocarcinoma (CCA) is the chemotherapy combination of gemcitabine plus cisplatin; only about 40% of patients are amenable to surgery. The objective of this retrospective study was to evaluate the clinical feasibility of the triplet chemotherapy regimen of nab-paclitaxel plus gemcitabine and cisplatin as first-line therapy in patients with locally advanced CCA.

The results were presented by Sung Hoon Choi, BA, CHA University, Seongnam-Si, South Korea, at the 2022 ASCO GI Cancers Symposium.

This retrospective analysis was based on a chart review of patients with locally advanced CCA who received the triplet regimen of nab-paclitaxel plus gemcitabine and cisplatin between October 2019 and December 2020. The feasibility of resection after induction chemotherapy was evaluated by a multidisciplinary team.

The investigators assessed the perioperative outcomes and pathologic results of surgical resection after induction chemotherapy.

Of the 85 patients in this study, 46 (54.1%) patients had measurable lesions, 24 patients had a diagnosis of intrahepatic CCA, 37 had extrahepatic/perihilar CCA, and 24 had extrahepatic/distal CCA.

In the overall population, after induction chemotherapy, the objective response rate in patients with measurable disease was 51.1%, and the disease control rate was 85.1%. Of the 85 patients in the study, 52 (61.2%) patients had resectable tumors.

Among all the patients in this study, 48 (56.5%) patients underwent subsequent curative surgery. In the subset of patients who underwent surgery, 6 (12.5%) achieved complete remissions (all in extrahepatic CCA); R0 resection was achieved in 43 (89.6%) patients.

The overall survival (OS) rates were significantly higher among patients who had induction chemotherapy followed by surgery compared with those who received chemotherapy alone, with a 12-month OS of 94.9% versus 72.6%, respectively (P = .009).

These data support the clinical feasibility of induction chemotherapy with nab-paclitaxel plus gemcitabine and cisplatin before curative surgery in patients with locally advanced CCA.

Source

Choi SH, Kang B, Cheon J, et al. Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma. Abstract 387.

Related Items

Characterization of Long-Term Survivors in TOPAZ-1
March 2023, Vol 4, No 1
Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.
MDM2-p53 Antagonist BI 907828 Demonstrated Promising Activity in Patients with Advanced BTC
March 2023, Vol 4, No 1
The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.
Treatment and Survival Outcomes with Systemic Therapy for Patients with BTC with IDH1 Mutations: A Retrospective Study
March 2023, Vol 4, No 1
Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.
Phase 2 Study of CTX-009 plus Paclitaxel in Patients with Advanced BTC
March 2023, Vol 4, No 1
CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.
Gunagratinib in Patients with Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements
March 2023, Vol 4, No 1
Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.
Results from SWOG 1815: GemCis and Nab-Paclitaxel versus GemCis in Advanced BTC
March 2023, Vol 4, No 1
The SWOG 1815 trial found that treatment with gemcitabine/cisplatin and paclitaxel (GAP) did not result in a significant improvement in survival compared with gemcitabine and cisplatin in patients with advanced biliary tract cancer, though GAP may be beneficial in patients with locally advanced disease and GBC.
JCOG1202 Subgroup Analysis: Risk Factors for Early Relapse in Patients Undergoing Curative Resection
March 2023, Vol 4, No 1
A study of patients with resected biliary tract cancer (BTC) found that postoperative CA 19-9 level, tumor differentiation, lymph node metastases, and residual tumor significantly impact early relapse in patients with curatively resected BTC. Similar risk factors were also found in patients receiving adjuvant S-1.
Impact of Gene Expression in 5-FU Metabolic Pathways on Outcomes in Patients Enrolled in JCOG1202
March 2023, Vol 4, No 1
Results from a study evaluating the impact of 5-FU metabolic pathway enzyme expression on outcomes of patients with curatively resected biliary tract cancer showed that relapse-free survival was improved in patients with certain enzymes who received adjuvant S-1.
Atezolizumab with or without Bevacizumab in Combination with GemCis in Advanced BTC: Results from IMbrave 151
March 2023, Vol 4, No 1
Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.
Nab-Paclitaxel plus Sintilimab as Second-Line Treatment for Advanced BTC
March 2023, Vol 4, No 1
The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: